BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 9815566)

  • 1. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
    Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
    Sayers TJ; Wiltrout TA; McCormick K; Husted C; Wiltrout RH
    Cancer Res; 1990 Sep; 50(17):5414-20. PubMed ID: 2117482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma.
    Younes E; Haas GP; Dezso B; Ali E; Maughan RL; Kukuruga MA; Montecillo E; Pontes JE; Hillman GG
    Cell Immunol; 1995 Oct; 165(2):243-51. PubMed ID: 7553889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism of local tumor irradiation combined with interleukin 2 therapy in murine renal carcinoma: histological evaluation of pulmonary metastases.
    Dezso B; Haas GP; Hamzavi F; Kim S; Montecillo EJ; Benson PD; Pontes JE; Maughan RL; Hillman GG
    Clin Cancer Res; 1996 Sep; 2(9):1543-52. PubMed ID: 9816331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
    Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
    Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of natural killer and T-cells in interferon induced inhibition of spontaneous metastases of the B16F10L murine melanoma.
    Markovic SN; Murasko DM
    Cancer Res; 1991 Feb; 51(4):1124-8. PubMed ID: 1705166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas.
    Hoon DS; Okun E; Banez M; Irie RF; Morton DL
    Cancer Res; 1991 Oct; 51(20):5687-93. PubMed ID: 1913686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases.
    Komschlies KL; Gregorio TA; Gruys ME; Back TC; Faltynek CR; Wiltrout RH
    J Immunol; 1994 Jun; 152(12):5776-84. PubMed ID: 8207207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration.
    Hara I; Nagai H; Miyake H; Yamanaka K; Hara S; Micallef MJ; Kurimoto M; Gohji K; Arakawa S; Ichihashi M; Kamidono S
    Cancer Gene Ther; 2000 Jan; 7(1):83-90. PubMed ID: 10678360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model.
    Hillman GG; Younes E; Visscher D; Ali E; Lam JS; Montecillo E; Pontes JE; Haas GP; Puri RK
    Cell Immunol; 1995 Feb; 160(2):257-63. PubMed ID: 7720087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
    Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
    Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
    Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
    Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.
    Nastala CL; Edington HD; McKinney TG; Tahara H; Nalesnik MA; Brunda MJ; Gately MK; Wolf SF; Schreiber RD; Storkus WJ
    J Immunol; 1994 Aug; 153(4):1697-706. PubMed ID: 7913943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
    Favrot M; Capdeville R; Combaret V; Zhou DC; Clapisson G; Banchereau J; Franks CR; Chouaib S; Blay JY; Philip T
    Eur Cytokine Netw; 1990; 1(3):141-7. PubMed ID: 2129798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
    Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
    J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
    Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
    Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.